Janssen has submitted two Marketing Authorisation Applications to the EMA for an investigational Ebola vaccine regimen.
List view / Grid view
Filter the results
A dengue fever vaccine candidate has demonstrated a high level of success in a Phase III trial, meeting its primary endpoints.
A new report has predicted that the global subcutaneous drug delivery devices market will grow to $17,290.47 million in 2027 from $9,243.80 million in 2018.
500,000 regimens of Janssen's investigational Ebola vaccine are to be donated to support the Ebola outbreak response in the Democratic Republic of the Congo.
The transition from egg-based towards cell-based, recombinant and universal influenza vaccines will drive growth in the seasonal influenza vaccine market, a report has said.
A candidate TB vaccine’s efficacy level and acceptable safety profile have been confirmed in a three-year clinical trial.
29 October 2019 | By Thermo Fisher Scientific
This webinar will present the use of the Thermo Scientific™ handheld Raman analyser TruScan™ RM with TruTools™ on-board chemometrics to verify the identity of challenging raw materials.
Nemera is a world leader in the design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology and generics industries. Nemera always puts patients first, providing high-quality solutions that have a demonstrable impact on patients’ health, including off-the-shelf innovative systems, customized design development and GMP contract manufacturing.
A drug capsule that can carry insulin and protect them from the harsh environment of the gastrointestinal tract has been developed.
Researchers have developed a series of lipid nanoparticles, which encapsulate RNA, for effective and improved vaccine delivery.
Researchers have developed a chikungunya vaccine that can be stored at warm temperatures and manufactured quickly, which has been validated in animal models.
New vaccine patch has showed no negative side effects and could lead to a replacement of needle-based vaccination methods.
Kenya has become the third African country to introduce the world’s first malaria vaccine into the country, in a phased pilot programme.